CD19-negative relapse with an apparent cytogenetic shift after blinatumomab-induced measurable residual disease clearance in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia [0.03%]
费城染色体阴性B细胞急性淋巴细胞白血病患者在经过blinatumomab治疗达到最小残留病灶阴性后的表观细胞遗传学改变及CD19阴性复发
Masuho Saburi,Reina Nagano,Rika Maruyama et al.
Masuho Saburi et al.
Blinatumomab, a CD3/CD19 bispecific T-cell engager, improves outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL), but CD19-negative relapse is an important mode of treatment failure. We report a 69-year-old woman with Philadelphia...
Synchronous presentation of pH+ B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia treated with blinatumomab [0.03%]
利妥昔单抗治疗pH+B细胞急性淋巴细胞白血病和慢性淋巴细胞白血病同步发作的病例报告
Christina Darwish,Don A Baldwin,Peter Abdelmessieh
Christina Darwish
CD19 directed immunotherapy with monoclonal antibodies and chimeric antigen receptor T (CAR-T) cell therapy has shown treatment efficacy in the relapsed/refractory setting for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (C...
Expression of SLAMF7 on hairy cell leukemia indicates therapy option with SLAMF7-antibody Elotuzumab [0.03%]
SLAMF7在毛细胞白血病中的表达表明可以使用SLAMF7抗体Elotuzumab进行治疗
Anju Singh,Mathis Bittermann,Ibrahim Hammada et al.
Anju Singh et al.
Corrigendum to Synergistic effects of arsenic trioxide and atorvastatin on proliferation and apoptosis in acute lymphoblastic leukemia cells [Leukemia Research Reports 25 (2026) 100570.1-1] [0.03%]
三氧化二砷和阿托伐他汀联合对急性淋巴细胞白血病细胞增殖及凋亡的影响一校正[《白血病研究报道》25卷(2026)100570.1-1]
Sepideh Hassanpour Khodaei,Shahnaz Sabetkam,Zeinab Mazloumi et al.
Sepideh Hassanpour Khodaei et al.
[This corrects the article DOI: 10.1016/j.lrr.2026.100570.]. © 2026 Published by Elsevier Ltd.
Published Erratum
Leukemia research reports. 2026 May 16:25:100593. DOI:10.1016/j.lrr.2026.100593 2026
Emphasizing the diagnostic and management challenge: Nodular sclerosis Hodgkin lymphoma with pericardial infiltration in an adolescent male - A case report [0.03%]
强调诊断和管理挑战：一名青少年男性结节硬化型霍奇金淋巴瘤伴心包浸润病例报告
Saja I AbuGhannam,Celina R Andonie,Leen I Masalmeh et al.
Saja I AbuGhannam et al.
Hodgkin's lymphoma is a malignancy of lymphoid tissue with a generally favorable prognosis; however, symptomatic initial presentation with pericardial involvement is rare and presents significant diagnostic and therapeutic challenges. We re...
Treatment outcomes of acute leukemia during pregnancy at the National Institute of Hematology and Blood Transfusion [0.03%]
国立血液学和输血研究所妊娠期急性白血病治疗结果
Bach Quoc Khanh,Nguyen Hong Son,Nguyen Quoc Nhat et al.
Bach Quoc Khanh et al.
Managing acute leukemia during pregnancy poses clinical challenges requiring a balance between maternal treatment and fetal preservation. From 2019 to 2024, 22 pregnant women were diagnosed with acute leukemia, including 7 acute lymphoblast...
Characteristics of immunoglobulin gene rearrangements in vietnamese newly diagnosed multiple myeloma patients [0.03%]
越南新诊断的多发性骨髓瘤患者免疫球蛋白基因重组的特征
Cao Sy Luan,Nguyen Vu Hai Son,Phan Ngo Quang Thach et al.
Cao Sy Luan et al.
Background: The immunoglobulin (IG) gene rearrangements provide valuable markers in monitoring minimal residual disease (MRD) after treatment in multiple myeloma (MM) patients. Methods: We conducted an observational study...
Incidental discovery of acquired factor X deficiency in a patient with multiple myeloma [0.03%]
偶发发现一例浆细胞瘤合并获得性因子X减少症
Yousra Sbibih,Mohammed Bensalah,Abderrazak Saddari et al.
Yousra Sbibih et al.
Factor X deficiency is a very rare coagulopathy caused by a constitutional or acquired deficiency of factor X, or by the presence of a circulating anticoagulant in the blood. Factor X deficiency has already been described in patients with A...
Evaluating the effectiveness of reduced-intensity conditioning regimens in acute myeloid leukemia patients after hematopoietic stem cell transplantation in Vietnam [0.03%]
评估造血干细胞移植后越南急性髓系白血病患者减量化疗方案的有效性
Man Van Huynh,Huu Than Huynh,Thu Hanh Nguyen et al.
Man Van Huynh et al.
Objective: Hematopoietic stem cell transplantation (HSCT) is an effective treatment for acute myeloid leukemia (AML) patients, leveraging cytotoxic conditioning regimens and graft-versus-leukemia effects. Reduced-intensit...
The role of RAS mutations in leukemia progression, differentiation, and drug resistance [0.03%]
RAS突变在白血病进展、分化和耐药中的作用
Congfa Jiang,Hangxuan Wang,Jiaxin Zhao et al.
Congfa Jiang et al.
Mutations in the RAS gene family (NRAS, KRAS) are critical drivers of late-stage acute myeloid leukemia (AML) progression. They are frequently detected in relapsed/refractory AML and AML transformed from myelodysplastic syndrome (MDS). Occu...